Glynex (Glycopyrronium Bromide, Neostigmine Methylsulfate)

Glynex is indicated for specific peri‑operative situations where rapid reversal of muscle relaxation is required.

• Reversal of non‑depolarizing neuromuscular blockade after general anesthesia.
• Restoration of spontaneous breathing and muscle tone in the immediate postoperative period.
• Prevention of muscarinic side‑effects such as bradycardia, salivation, and bronchial secretions during reversal.
• Facilitation of safe extubation and transfer to recovery areas.
• Optional use in diagnostic procedures that involve temporary neuromuscular blockade.

The pharmacologic actions of Glynex can produce a range of observable effects, most of which are transient.

Common

• Dry mouth or reduced salivation.
• Mild tachycardia or palpitations.
• Nausea or mild gastrointestinal discomfort.
• Transient muscle fasciculations.
• Flushing or warmth sensation.

Serious

• Bradycardia or severe heart rate abnormalities.
• Hypotension or significant blood pressure drop.
• Bronchospasm or respiratory distress.
• Allergic reactions including rash, urticaria, or anaphylaxis.
• Excessive cholinergic activity leading to muscle weakness or paralysis.

When using Glynex, clinicians should observe several precautionary measures to minimize risk.

• Assess baseline cardiac function and monitor heart rate and blood pressure continuously.
• Verify adequate spontaneous ventilation before administration.
• Adjust dose in patients with renal or hepatic impairment, as drug clearance may be reduced.
• Use caution in individuals with known hypersensitivity to anticholinergic or cholinesterase‑inhibiting agents.
• Avoid use in patients with uncontrolled asthma or severe bronchospastic disease.
• Document neuromuscular monitoring results to guide dosing and timing.

Glynex may interact with other medications that affect cholinergic transmission or cardiovascular function.

Avoid

• Concurrent use of other anticholinergic agents that could exacerbate dry mouth or tachycardia.
• Strong cholinesterase inhibitors administered for unrelated indications, which may amplify neuromuscular effects.
• Beta‑blockers or calcium‑channel blockers that could mask tachycardia signs.

Use with caution

• Opioid analgesics, as they may depress respiratory drive when combined with reversal agents.
• Neuromuscular blocking agents, requiring careful timing to prevent cumulative effects.
• Diuretics or antihypertensives, due to potential additive blood pressure changes.